⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523251 | 0.59 | — | — | |
| SCHEMBL12628829 | 0.57 | — | — | |
| SCHEMBL260537 | 0.55 | — | — | |
| SCHEMBL14096697 | 0.55 | — | — | |
| SCHEMBL418167 | 0.55 | — | — | |
| SCHEMBL416052 | 0.55 | — | — | |
| SCHEMBL14740877 | 0.55 | — | — | |
| SCHEMBL5817024 | 0.55 | — | — | |
| SCHEMBL25429315 | 0.54 | — | — | |
| Hydrochloric Acid SCHEMBL4624279 | 0.54 | CCR5 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2024-07-04 | — | — | US | claimed |
| EP-4320125-A1 | PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2024-02-14 | — | — | EP | claimed |
| CN-117396477-A | Pyridyl-substituted oxoisoindoline compounds for the treatment of cancer | 百时美施贵宝公司 | 2024-01-12 | — | — | CN | claimed |
| EP-4272737-A2 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | Celgene Corporation (US) | 2023-11-08 | — | — | EP | claimed |
| EP-3784663-B1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | CELGENE CORP (US) | 2023-07-12 | — | — | EP | claimed |
| EP-3414247-B1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | claimed |
| EP-3784663-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND THEIR USE FOR TREATING LYMPHOMA | Celgene Corporation (US) | 2021-03-03 | — | — | EP | claimed |
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-04-14 | — | — | US | claimed |
| US-20190322647-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2019-10-24 | — | — | US | claimed |
| US-20190071444-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-03-07 | — | — | US | claimed |
| EP-2970278-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | AbbVie Inc. (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014139328-A1 | PYRROLO[2,3-B]PYRIDINE CDK9 KINASE INHIBITORS | ABBVIE INC. (US) | 2014-09-18 | — | — | WO | claimed |
| US-7795294-B2 | Tetrahydro-2H-indazole pyrazole cannabinoid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-14 | — | — | US | claimed |
| US-20080058313-A1 | TETRAHYDRO-2H-INDAZOLE PYRAZOLE CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-03-06 | — | — | US | claimed |
| EP-1309596-B1 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2007095513-A1 | TETRAHYDR0-2H-INDAZ0LE DERIVATIVES FOR USE AS CANNABINOID MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2007-08-23 | — | — | WO | claimed |
| EP-1309596-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-05-14 | — | — | EP | claimed |
| US-6489328-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIALLERGENS; ANTIPROLIFERATIVE AGENTS; ANTICANCER AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-12-03 | — | — | US | claimed |
| US-20020119975-A1 | Heterocyclic compounds useful as inhibitors of tyrosine kinases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-08-29 | — | — | US | claimed |
| WO-2002014319-A2 | HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-02-21 | — | — | WO | claimed |